- Home
- CRVO vs EPIX Comparison
CRVO vs EPIX Comparison
Compare CRVO & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- EPIX
- Stock Information
- Founded
- CRVO 2001
- EPIX 2009
- Country
- CRVO United States
- EPIX Canada
- Employees
- CRVO N/A
- EPIX N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- EPIX Health Care
- Exchange
- CRVO Nasdaq
- EPIX Nasdaq
- Market Cap
- CRVO 67.4M
- EPIX 75.9M
- IPO Year
- CRVO N/A
- EPIX N/A
- Fundamental
- Price
- CRVO $5.56
- EPIX $1.70
- Analyst Decision
- CRVO Strong Buy
- EPIX Hold
- Analyst Count
- CRVO 8
- EPIX 3
- Target Price
- CRVO $25.57
- EPIX $2.00
- AVG Volume (30 Days)
- CRVO 137.9K
- EPIX 54.8K
- Earning Date
- CRVO 08-08-2025
- EPIX 08-04-2025
- Dividend Yield
- CRVO N/A
- EPIX N/A
- EPS Growth
- CRVO N/A
- EPIX N/A
- EPS
- CRVO N/A
- EPIX N/A
- Revenue
- CRVO $9,308,215.00
- EPIX N/A
- Revenue This Year
- CRVO N/A
- EPIX N/A
- Revenue Next Year
- CRVO N/A
- EPIX N/A
- P/E Ratio
- CRVO N/A
- EPIX N/A
- Revenue Growth
- CRVO 15.14
- EPIX N/A
- 52 Week Low
- CRVO $1.80
- EPIX $1.40
- 52 Week High
- CRVO $20.63
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- CRVO 30.87
- EPIX 48.47
- Support Level
- CRVO $6.31
- EPIX $1.60
- Resistance Level
- CRVO $7.20
- EPIX $1.73
- Average True Range (ATR)
- CRVO 0.53
- EPIX 0.05
- MACD
- CRVO -0.10
- EPIX -0.00
- Stochastic Oscillator
- CRVO 0.00
- EPIX 44.44
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.